Neuropharmacology & Neurotherapeutics
Propofol
Sep. 12, 2021
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
(Left side) Functional alpha-gal-A activity in a person with no mutation in GLA gene or absent activity. As a result, there is no accumulation of unwanted substrate in the lysosome. Also, the enzyme is responsible for removing the terminal galactose sugar from Gb-3, which leads to the formation of lactosylceramide (LacCer). (Right side) The function of alpha-gal-A is altered due to the presence of a mutation in the GLA gene. The latter leads to a buildup of Gb-3. Thus, an accumulation of dysfunctional lysosomes occurs within the cell.
Abbreviations: alpha-gal-A, alpha-galactosidase A; Cer, ceramide; Gal, galactose; Gb-3, globotriaosylceramide; Glu, glucose; LacSer, lactosylceramide; Lysoo-Gb3, globotriaosulsphingosine.
(Source: Coelho-Ribeiro B, Silva HG, Sampaio-Marques B, et al. Inflammation and exosomes in Fabry disease pathogenesis. Cells 2024;13[8]:654. Adapted from: Rocchetti MT, Spadaccino F, Catalano V, et al. Metabolic fingerprinting of Fabry disease: diagnostic and prognostic aspects. Metabolites 2022;12[8]:703. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)